Table 3 Quantitative volumetric analysis of changes in contrast-enhanced tumor and fluid attenuated inversion recovery volumes over the study period
| Â | Â | Baseline | 6-month | 12-month |
|---|---|---|---|---|
CET (mL) | Cohort 1 | 18.7 (1.3) | 14.6 (3.6) | 12.7 (4.7) |
Cohort 2 | 26.1 (8.5) | 16.8 (8.7) | 13.4 (9.5) | |
Cohort 3 | 27 (6.4) | 12.4 (10.3) | 10.5 (10.4) | |
PR | 24.2 (5.9) | 10 (4.6) | 7.2 (2.3) | |
SD | 25.7 (9.2) | 22.1 (8.4) | 21.1 (8.9) | |
Overall | 24.7 (6.7) | 14 (8.3) | 11.8 (8.5) | |
P-value†| – | 0.002* | 0.002* | |
FLAIR (mL) | Cohort 1 | 145.7 (15.4) | 138.7 (14.7) | 134.5 (13) |
Cohort 2 | 191.1 (34) | 160.9 (10.7) | 161.9 (12.5) | |
Cohort 3 | 151.2 (25.1) | 107.5 (19.7) | 101.9 (20.8) | |
PR | 157.8 (26.7) | 118.7 (27.3) | 113.9 (29.7) | |
SD | 163.7 (40.1) | 148.6 (19.2) | 147.3 (20.1) | |
Overall | 159.8 (30) | 128.6 (28.2) | 125 (30.7) | |
P-value†| – | 0.005* | 0.005* |